Analyzing the TK activity in RCC cell line and patient samples, Haake et al. revealed numerous unique tyrosine phosphosites in EGFR, MET, JAK2, and FAK [67], highlighting the strong potential for therapeutic targeting. Here, PTK2 is linked to renal cell carcinoma.